1 / 8

Hot Topics

Hot Topics. What’s new?. Oral therapies; Cladribine Fingolimod Fampridine Sativex MS related guidelines Publications Websites. Cladribine. is a licensed cytotoxic agent for hairy cell leukaemia, license for MS expected 2011

eshana
Download Presentation

Hot Topics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hot Topics

  2. What’s new? Oral therapies; • Cladribine • Fingolimod • Fampridine • Sativex MS related guidelines Publications Websites

  3. Cladribine • is a licensed cytotoxic agent for hairy cell leukaemia, license for MS expected 2011 • reduces or eliminates many cell types involved in MS e.g. T cells and B cells • reduces relapse rate by 58% (CLARITY study 2010) • dose dependant on weight • yearly course - taken once daily for 5 consecutive days repeated after four weeks • treatment for two years • has significant side effects including serious infections and raised risk of cancer

  4. Fingolimod • licence expected 2011 • retains circulating lymphoctes in the lymph nodes • has anti inflammatory properties by reducing infiltrating T cells and macrophages in CNS • taken daily 0.5mg reduces, relapse rate by 54% (FREEDOM study 2010) • can cause reduction in lymphocytes • other side effects include bradycardia with first dose, cardiac irregularities, opportunistic infections, may predispose to malignancies especially skin cancers, macular oedema

  5. Fampridine (Ampyra) • Potassium channel blocker • Improves function of demyelinated axons • Improves walking speed • High dose causes seizure • Can be used in conjunction with disease modifying therapies • Contraindications – history of seizure, renal insufficiency

  6. Sativex • cannabis based treatment administered as sub lingual spray • full license expected 2010 • indications; second line treatment for spasticity, not likely to be licensed for pain • Side effects include sedation, neuropsychiatric effects, dizziness, fatigue, mucosal irritation

  7. New Guidelines • Functional stimulation for foot drop of central neurological origin (NICE 2009) • UK consensus on the management of the bladder in MS (Fowler, C. J. et al 2009) • Neuropathic Pain: the pharmacological management of neuropathic pain in adults in non specialist settings (NICE 2010)

  8. What’s new • MS Trust publication; MS and me (a self management guide to living with MS) • www.stayingsmart.org.uk (online resource for managing cognitive impairment) • www.shift.ms (website aimed at young people with MS)

More Related